L&C Bio Obtains US Patent for Skin ECM-Based Wound Care Technology
Predicted impact: Low
US patent registration for wound-care technology; small, and the patent was already reported.
L&C Bio엘앤씨바이오
290650 · KOSDAQ · ₩290650 · 엘앤씨바이오
₩25,100▲ ₩150 (0.60%)End-of-day · Oct 29, 2026 · End-of-day prices.
L&C Bio: Patent for wound-treatment material using human skin tissue in the US
Predicted impact: Low
Same US wound-treatment patent news as the other item in this batch.
L&C Bio secures US patent for wound-healing material; expands MegaCure deployment
Predicted impact: Low
US patent for wound-healing material; small relative to ₩671.5B market value, no revenue size given.
L&C Bio Blocks Illegal Distribution of Beauty Injection 'Rituo'
Predicted impact: Low
Enforcement against illegal distribution is routine; no size given for financial impact.
L&C Bio Introduces Breast Reconstruction Case Using MegaFill at Conference
Predicted impact: Low
Academic conference case presentation; rights offering already reported earlier.
L&C Bio presents skin ECM product 'Rituo' at plastic surgery academic conference
Predicted impact: Low
Product presentation at a conference; rights offering already reported earlier.
L&C Bio completes ₩144.7B rights offering subscription, invests in Dongtan production base
Predicted impact: Medium· Actual: −0.7% vs sector, volume 1.6× normal (5 trading days)
Rights offering of ₩144.7B is about 9.5% of market value, but the subscription completion is a follow-up to earlier coverage.
L&C Bio rights offering: existing shareholder subscription rate at 103.92%
Predicted impact: Low· Actual: −0.7% vs sector, volume 1.6× normal (5 trading days)
Subscription rate result of the same rights offering already flagged; lowered one level.
L&C BIO raises ₩144.7B through rights offering
Predicted impact: Medium· Actual: −0.7% vs sector, volume 1.6× normal (5 trading days)
Rights offering raising ₩144.7B, about 9.5% of market value; well above the 5% dilution threshold.
L&C Bio’s Re2O Secures UAE Import Approval, Opening Door to Middle East
Predicted impact: Low· Actual: −2.2% vs sector, volume 1.9× normal (5 trading days)
UAE import approval for a product; no revenue size given, so modest commercial impact.
L&C Bio Ritubo obtains UAE import permit… Middle East market expands
Predicted impact: Low· Actual: +2.2% vs sector, volume 2.2× normal (5 trading days)
UAE import permit for a product; market expansion with unknown revenue size.
L&C Bio jumps over 10% in after-market trading
Predicted impact: Low· Actual: +10.5% vs sector, volume 3.1× normal (5 trading days)
After-hours share jump; no company news disclosed.
Also known as: L&C Bio / 엘앤씨바이오 / 290650 / KRX:290650
Source: KRX statistical information